In a strategic move to boost its presence in the Aussie market, healthcare tech company Austco Healthcare (ASX:AHC) has revealed its intention to acquire Victorian-based Teknocorp Australia and its Victorian Monitoring Services division conditionally. The acquisition, valued at $3.8 million, marks a significant step for Austco attempting to replicate its direct sales model implemented in
Read More
With a super on-the-nose name, it’s difficult not to know what UK-based telehealth company Doctor Care Anywhere (ASX: DOC) does. Providing people consultations no matter where they are, the Company seems to have received public favour, with a spurt in the number of returning customers and thriving subsidiaries. At the same time, this was probably
Read More
In a shocking turn of events, the Therapeutic Goods Australia (TGA) —the medicine regulatory authority in the country—has rejected medtech company Hydrix’s (ASX: HYD) application to distribute its cardiovascular device, Guardian, in Australia. The TGA was dissatisfied with the device’s effectiveness. According to the regulatory body, the AngelMed Guardian device didn’t demonstrate that the benefits
Read More
In the mood for some NICE advice? Here goes: The UK’s National Institute for Health and Care Excellence (NICE) has published a MedTech Innovation Briefing on PromarkerD, i.e. a predictive blood test determining diabetes kidney disease (DKD). The Briefing, dubbed NICE advice, reports that PromarkerD is effective at predicting renal function decline in people with
Read More
Over 100 million people worldwide suffer from glaucoma—a cocktail of eye infections resulting in blindness. Though glaucoma has no cure, some treatments can aid vision loss, slowing down its progression or intensity. One such treatment is MedTech company Nova Eye Medical’s (ASX: EYE) glaucoma surgical devices, which witnessed sales revenue of $5.66 million between July
Read More
To sell in the US market, every foreign company needs the support of locals. For medtech company Singular Health Group (ASX: SHG), that is Kelyniam Global Inc. The Company has appointed Kelyniam as its US-based agent—a key appointment and integral pre-requisite to satisfy the final FDA regulatory requirement, prior to Singular Health entering the US.
Read More